315 related articles for article (PubMed ID: 25676388)
1. Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease.
Karami A; Eyjolfsdottir H; Vijayaraghavan S; Lind G; Almqvist P; Kadir A; Linderoth B; Andreasen N; Blennow K; Wall A; Westman E; Ferreira D; Kristoffersen Wiberg M; Wahlund LO; Seiger Å; Nordberg A; Wahlberg L; Darreh-Shori T; Eriksdotter M
Alzheimers Dement; 2015 Nov; 11(11):1316-28. PubMed ID: 25676388
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device.
Eyjolfsdottir H; Eriksdotter M; Linderoth B; Lind G; Juliusson B; Kusk P; Almkvist O; Andreasen N; Blennow K; Ferreira D; Westman E; Nennesmo I; Karami A; Darreh-Shori T; Kadir A; Nordberg A; Sundström E; Wahlund LO; Wall A; Wiberg M; Winblad B; Seiger Å; Wahlberg L; Almqvist P
Alzheimers Res Ther; 2016 Jul; 8(1):30. PubMed ID: 27389402
[TBL] [Abstract][Full Text] [Related]
3. Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor.
Ferreira D; Westman E; Eyjolfsdottir H; Almqvist P; Lind G; Linderoth B; Seiger A; Blennow K; Karami A; Darreh-Shori T; Wiberg M; Simmons A; Wahlund LO; Wahlberg L; Eriksdotter M
J Alzheimers Dis; 2015; 43(3):1059-72. PubMed ID: 25147108
[TBL] [Abstract][Full Text] [Related]
4. Analysis of cerebrospinal fluid of Alzheimer patients. Biomarkers and toxic properties.
Marksteiner J; Pirchl M; Ullrich C; Oberbauer H; Blasko I; Lederer W; Hinterhuber H; Humpel C
Pharmacology; 2008; 82(3):214-20. PubMed ID: 18810245
[TBL] [Abstract][Full Text] [Related]
5. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
[TBL] [Abstract][Full Text] [Related]
6. Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment.
Nordberg A; Kadir A; Andreasen N; Almkvist O; Wall A; Långström B; Zetterberg H
J Alzheimers Dis; 2015; 47(3):691-704. PubMed ID: 26401704
[TBL] [Abstract][Full Text] [Related]
7. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
[TBL] [Abstract][Full Text] [Related]
8. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
10. Cholinergic dysfunction, neurodegeneration, and amyloid-beta pathology in neurodegenerative diseases.
Petrova T; Orellana C; Jelic V; Oeksengaard AR; Snaedal J; Høgh P; Andersen BB; Naik M; Engedal K; Wahlund LO; Ferreira D
Psychiatry Res Neuroimaging; 2020 Aug; 302():111099. PubMed ID: 32505903
[TBL] [Abstract][Full Text] [Related]
11. Fast Alpha Activity in EEG of Patients With Alzheimer's Disease Is Paralleled by Changes in Cognition and Cholinergic Markers During Encapsulated Cell Biodelivery of Nerve Growth Factor.
Eyjolfsdottir H; Koenig T; Karami A; Almqvist P; Lind G; Linderoth B; Wahlberg L; Seiger Å; Darreh-Shori T; Eriksdotter M; Jelic V
Front Aging Neurosci; 2022; 14():756687. PubMed ID: 35557841
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy.
Khan TK; Alkon DL
J Alzheimers Dis; 2015; 46(4):817-36. PubMed ID: 26402622
[TBL] [Abstract][Full Text] [Related]
13. Repeated nicotine exposure in rats: effects on memory function, cholinergic markers and nerve growth factor.
Hernandez CM; Terry AV
Neuroscience; 2005; 130(4):997-1012. PubMed ID: 15652996
[TBL] [Abstract][Full Text] [Related]
14. Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study.
Pentz R; Iulita MF; Ducatenzeiler A; Videla L; Benejam B; Carmona‐Iragui M; Blesa R; Lleó A; Fortea J; Cuello AC
Alzheimers Dement; 2021 Apr; 17(4):605-617. PubMed ID: 33226181
[TBL] [Abstract][Full Text] [Related]
15. Increased Active OMI/HTRA2 Serine Protease Displays a Positive Correlation with Cholinergic Alterations in the Alzheimer's Disease Brain.
Darreh-Shori T; Rezaeianyazdi S; Lana E; Mitra S; Gellerbring A; Karami A; Bogdanovic N; Lithner CU; Winblad B; Behbahani H
Mol Neurobiol; 2019 Jul; 56(7):4601-4619. PubMed ID: 30361890
[TBL] [Abstract][Full Text] [Related]
16. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid from Alzheimer patients affects cell-mediated nerve growth factor production and cell survival in vitro.
Eriksdotter M; Navarro-Oviedo M; Mitra S; Wahlberg L; Linderoth B; Tjernberg LO; Behbahani H
Exp Cell Res; 2018 Oct; 371(1):175-184. PubMed ID: 30092220
[TBL] [Abstract][Full Text] [Related]
18. Regulated Extracellular Choline Acetyltransferase Activity- The Plausible Missing Link of the Distant Action of Acetylcholine in the Cholinergic Anti-Inflammatory Pathway.
Vijayaraghavan S; Karami A; Aeinehband S; Behbahani H; Grandien A; Nilsson B; Ekdahl KN; Lindblom RP; Piehl F; Darreh-Shori T
PLoS One; 2013; 8(6):e65936. PubMed ID: 23840379
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
20. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
